Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

End Of An Era As Generic Versions Of BMS’s Controversial Blockbuster Revlimid Arrive

Gradual Decline From $12bn Peak Expected

Executive Summary

Revlimid was the driving force behind Celgene’s growth, but also became symbolic in the ongoing row over US drug prices.

You may also be interested in...



Dr Reddy’s Debuts Two Revlimid Exclusives As Part Of Complete Launch In US

Dr Reddy’s Laboratories is set to reap the rewards of a significant US generic launch – albeit one with a limited volume caveat decreed by a patent-litigation settlement deal – after it began selling its generic of Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid.

BMS Gets First Immunotherapy Approval In Neoadjuvant Lung Cancer, Quickly

Opdivo gets approved by the US FDA for neoadjuvant non-small cell lung cancer, an important new early-stage indication for the anti-PD-1 agent that cleared the agency in roughly two months.

Teva Pounces On US Revlimid Opportunity With Four Strength-Offering

Teva has bolstered its oncology offering in the US by moving first on one of the largest small-molecule opportunities in the US: Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) to treat multiple myeloma.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel